<DOC>
	<DOCNO>NCT00798369</DOCNO>
	<brief_summary>This 8-week study design determine target dose canakinumab ( ACZ885 ) management acute flare gout patient contraindicate Non-Steroidal anti-inflammatory drug and/or colchicine . The efficacy ACZ885 compare corticosteroid triamcinolone acetonide .</brief_summary>
	<brief_title>Targeted Dose Finding Canakinumab ( ACZ885 ) Management Acute Flare Refractory Contraindicated Gout Patients</brief_title>
	<detailed_description />
	<mesh_term>Gout</mesh_term>
	<mesh_term>Colchicine</mesh_term>
	<mesh_term>Triamcinolone hexacetonide</mesh_term>
	<mesh_term>Triamcinolone Acetonide</mesh_term>
	<mesh_term>Triamcinolone</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Triamcinolone diacetate</mesh_term>
	<criteria>History least 1 gout flare prior Screening Visit Meeting American College Rheumatology ( ACR ) 1977 preliminary criterion classification acute arthritis primary gout . Presence acute gout flare longer 5 day . Baseline pain intensity &gt; = 50 mm 0100 mm VAS . Contraindicated , intolerant unresponsive NSAIDs , colchicine . Rheumatoid arthritis , evidence/suspicion infectious/septic arthritis , acute inflammatory arthritis . Presence severe renal function impairment Contraindication intramuscular injection Known presence suspicion active recurrent bacterial , fungal viral infection time enrollment Evidence active pulmonary disease Live vaccination within 3 month prior start study Use forbidden therapy Other protocoldefined inclusion/exclusion criterion apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Acute flare</keyword>
	<keyword>Gout</keyword>
	<keyword>Anti-interleukin-1Î² monoclonal antibody</keyword>
	<keyword>Colchicine</keyword>
	<keyword>Triamcinolone acetonide</keyword>
</DOC>